title: Bipolar disorders, type 2 diabetes mellitus, and the brain.
abstract: OBJECTIVE
  Type 2 diabetes mellitus (T2DM) negatively affects brain structure and function. Meta-analytical data show that relative to age and sex matched non-psychiatric controls, patients with bipolar disorders have double the risk of T2DM. We review the evidence for association between T2DM and adverse clinical and brain imaging changes in bipolar disorders and summarize studies investigating effects of diabetes treatment on psychiatric and brain outcomes.
  
  
  RESULTS
  Participants with bipolar disorders and T2DM or insulin resistance demonstrate greater morbidity, chronicity and disability, and lower treatment response to Li. Bipolar disorders complicated by insulin resistance/T2DM are associated with smaller hippocampal and cortical gray matter volumes and lower prefrontal N-acetyl aspartate (neuronal marker). Treatment of T2DM yields preservation of brain gray matter and insulin sensitizers, such as pioglitazone, improve symptoms of depression in unipolar or bipolar disorders.
  
  
  CONCLUSIONS
  T2DM or insulin resistance frequently cooccur with bipolar disorders and are associated with negative psychiatric clinical outcomes and compromised brain health. This is clinically concerning, as patients with bipolar disorders have an increased risk of metabolic syndrome and yet often receive suboptimal medical care. At the same time treatment of T2DM and insulin resistance has positive effects on psychiatric and brain outcomes. These findings create a rich agenda for future research, which could enhance psychiatric pharmacopeia and directly impact patient care.
authors.affiliation: aDepartment of Psychiatry, Dalhousie University, Halifax, CanadabNational Institute of Mental Health, Klecany, Czech RepubliccDepartment of Psychiatry, University of Toronto, Toronto, Canada.
authors.forename: Tomas
authors.initials: T
authors.lastname: Hajek
authors.forename: Roger
authors.initials: R
authors.lastname: McIntyre
authors.forename: Martin
authors.initials: M
authors.lastname: Alda
mesh_terms: D001714:Bipolar Disorder / Q000097:blood / Q000378:metabolism / Q000473:pathology* / Q000523:psychology; D001921:Brain / Q000473:pathology* / Q000503:physiopathology*; D003863:Depression / Q000188:drug therapy / Q000209:etiology; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy / Q000473:pathology* / Q000503:physiopathology / Q000523:psychology*; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use*; D007333:Insulin Resistance
chemical_list: D007004:Hypoglycemic Agents